BMY stock: buy or sell?
September 20th, 2019
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide.
Should I buy BMY stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Bristol-Myers Squibb stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Bristol-Myers Squibb stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we collected 15 ratings published for BMY stock in the last 30 days. The general sentiment of these ratings is bullish for BMY stock, with 9 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-3||Bank of America||n/a||Neutral|
|2019-5-3||JPMorgan Chase & Co.||Overweight||Overweight|
|2019-5-3||JPMorgan Chase & Co.||n/a||Overweight|
|2019-5-28||Goldman Sachs Group||n/a||Buy|
|2019-3-20||BMO Capital Markets||n/a||Outperform|
|2019-2-4||Credit Suisse Group||n/a||Hold|
|2019-2-19||BMO Capital Markets||n/a||Buy|
|2019-2-19||Bank of America||Neutral||Hold|
|2019-2-15||Credit Suisse Group||n/a||Hold|
|2019-1-3||BMO Capital Markets||n/a||Buy|
BMY stock analysis
Shares of Bristol-Myers Squibb closed today at $50.57 and stepped up a tiny 1.00%.
Bristol-Myers Squibb shares stepped up 1.00% to $50.57 today. In the last 25 days when BMY stock price broke up the SMA200d line, it gained $3.99 (8.57%). For the last 8 days when SMA50d and SMA100d crossed up, BMY price gained $1.33 per share (2.70%).
Bristol-Myers Squibb stepped up a fine 2.31% this week. Counting this, it's been 4 green weeks in a row, gaining $3.99 or 8.49%.
Since late August when BMY stock price broke up the SMA40w line, it gained $3.99 (8.57%).
BMY stock price history
BMY stock historical price chart
BMY stock reached 52-week highs on October at $62.09, and all-time highs 2016-07-15 with a price of 70.79.
BMY stock price target is $56.50How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' BMY stock price predictions in the hope that they will be met as they may be wrong and not met. We found 11 price predictions for Bristol-Myers Squibb stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-3||Bank of America||Raises Target||$46.00||$49.00||6.5%|
|2019-6-13||UBS Group||Lowers Target||$55.00||$51.00||-7.3%|
|2019-5-3||JPMorgan Chase & Co.||Reiterates||n/a||$62.00||-|
|2019-5-28||Goldman Sachs Group||Initiates||n/a||$54.00||-|
|2019-3-20||BMO Capital Markets||Raises Target||n/a||$62.00||-|
|2019-2-4||Credit Suisse Group||Set Price Target||n/a||$59.00||-|
|2019-2-19||BMO Capital Markets||Reiterates||n/a||$59.00||-|
|2019-2-19||Bank of America||Reiterates||$53.00||$51.00||-3.8%|
|2019-2-15||Credit Suisse Group||Reiterates||n/a||$59.00||-|
|2019-1-3||BMO Capital Markets||Reiterates||n/a||$60.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last April, when Bristol-Myers Squibb published its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a pretty good increase of 8.59% to $22,561.00 M dollars. Aligned with this, its income margin (compared to sales) boosted to 21.81%, that is $4,920.00 million. Bristol-Myers Squibb fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Bristol-Myers Squibb TTM sales up to March 2019 were $23,288.00 and income $5,144.00 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Bristol-Myers Squibb business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, appreciated a beatiful 3.22%. Nonetheless, profit margin (net income/revenues) stayed steady at 21.81%.
|2013||$16,390 M||-||$2,560 M15.6%||-|
|2014||$15,879 M||-3.12%||$2,004 M12.6%||-21.72%|
|2015||$16,560 M||4.29%||$1,565 M9.5%||-21.91%|
|2016||$19,427 M||17.31%||$4,457 M22.9%||184.79%|
|2017||$20,776 M||6.94%||$1,007 M4.8%||-77.41%|
|2018||$22,561 M||8.59%||$4,920 M21.8%||388.58%|
|TTM||$23,288 M||3.22%||$5,144 M22.1%||4.55%|
Quarterly financial resultsBristol-Myers Squibb reported $5,920.00 million in revenues for 2019-Q1, a -0.89% less compared to previous quarter. Reported quarter earnings marked $1,710.00 million with a profit margin of 28.89%. Profit margin rose a 9.46% compared to previous quarter when profit margin was 19.42%. When comparing sales to same quarter last year, Bristol-Myers Squibb sales marked an outstanding growth and climbed a 14.00%.
|2017-Q2||$5,140 M||-||$916 M17.8%||-|
|2017-Q3||$5,250 M||2.14%||$845 M16.1%||-7.75%|
|2017-Q4||$5,449 M||3.79%||$-2,328 M-42.7%||-375.50%|
|2018-Q1||$5,193 M||-4.70%||$1,486 M28.6%||-163.83%|
|2018-Q2||$5,704 M||9.84%||$373 M6.5%||-74.90%|
|2018-Q3||$5,691 M||-0.23%||$1,901 M33.4%||409.65%|
|2018-Q4||$5,973 M||4.96%||$1,160 M19.4%||-38.98%|
|2019-Q1||$5,920 M||-0.89%||$1,710 M28.9%||47.41%|
Bristol-Myers Squibb ownershipWhen you are planning to buy shares of a company, it's always worth to have a look its ownership structure.
Bristol-Myers Squibb shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.11% of all shares.
In case of Bristol-Myers Squibb stock, 75.05% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BMY stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$82.9 B|
|Total shares||1,640.0 M|
|Float shares||1,630.0 M|
|- Institutional holdings (%)||75.0%|
|- Insider holdings (%)||0.1%|
|Shares in short selling||0.0%|
|Friday, September 20th, 2019|
|Day range||$49.99 - $50.86|
|Average true range||$0.84|
|50d mov avg||$46.78|
|100d mov avg||$46.55|
|200d mov avg||$47.51|
Bristol-Myers Squibb performanceTo better understand Bristol-Myers Squibb performance you must compare its gains with other related stocks in same sector or industry. We selected as the bechmarking frame for Bristol-Myers Squibb stock.
Bristol-Myers Squibb competitorsUnfortunately, we could not find any public company that could be defined as Bristol-Myers Squibb competitor. This doesn't mean Bristol-Myers Squibb does not have any competitor in the market, it's just we could not detected it.
Latest BMY stock news
- InvestorPlaceBristol-Myers Squibb Earnings: BMY Stock Bounces on Strong Q2, GuidanceJuly 25, 2019
- InvestorPlaceWhy Bristol-Myers Squibb Stock Is Stumbling Ahead of EarningsJuly 23, 2019
- Seeking AlphaBristol-Myers Squibb Is CheapJuly 3, 2019
- Seeking AlphaBristol-Myers Squibb And Celgene - On The Path To A Valuable CombinationJune 20, 2019
- InvestorPlaceBristol-Myers Squibb Earnings: BMY Stock Pops on Q1 BeatApril 25, 2019